DDInter1881 DDInter119
Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zaleplon
Troglitazone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lipoic acid
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Insulin glargine
Troglitazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ramelteon
Troglitazone {u} may lead to a major life threatening interaction when taken with {v} Mipomersen
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Zaleplon
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lipoic acid
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine
Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Ramelteon
Troglitazone may lead to a major life threatening interaction when taken with Mipomersen